[Drug combinations: statins and niacin].
Combination of statins with niacin appears to be an attractive association, in the presence of mixed dyslipidemia with low HDL-c levels, when monotherapy is insufficient to achieve target lipid levels. Clinical benefits were observed by the combination of statins with niacin in the FATS, HATS and ARBITER 2 trials, showing attenuation of atherosclerosis development and/or reduction in coronary events following favorable lipid changes. In general, this combination can be well-tolerated. Recommendations for appropriate monitoring of liver and muscle enzymes are important to reduce the rate of side effects. In addition, careful titration of each drug is recommended.
Borges
Jairo Lins
JL
Seção clínica de Cardiogeriatria, Instituto Dante Pazzanese de Cardiologia de São Paulo.
D017677:Age Distribution; D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism; D000069059:Atorvastatin; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D009525:Niacin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D012737:Sex Factors; D019821:Simvastatin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D009525:Niacin; D000069059:Atorvastatin; D019821:Simvastatin